Centrus Energy is a trusted supplier of nuclear fuel and services for the nuclear power industry. Centrus provides value to its utility customers through the reliability and diversity of its supply sources – helping them meet the growing need for clean, affordable, carbon-free electricity. Since 1998, the Company has provided its utility customers with more than 1,750 reactor years of fuel, which is equivalent to 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is also advancing the next generation of centrifuge technologies so that America can restore its domestic uranium enrichment capability in the future. Find out more at www.centrusenergy.com.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

USALCO is the premier manufacturer of various aluminum-based chemicals, such as aluminum sulfate, sodium aluminate, polyaluminum chloride, aluminum chlorohydrate, and aluminum chloride, to industrial and municipal markets. USALCO’s Polyaluminum Chloride (PACL) products, DelPAC® and UltraPAC®, have become the coagulants of choice in well over 1,000 water treatment applications throughout the US. USALCO’s research and development staff is committed to continuously innovating new coagulant chemistry to address the ever-changing regulatory landscape. Coupled with our on-site application expertise, USALCO is uniquely positioned to meet the increasing customer demand for improved treatment results at a lower total cost. Our company headquarters is in Baltimore, Maryland which is also the site of the largest aluminum coagulant manufacturing plant in North America. USALCO operates at 31 facilities throughout the United States.

Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

In Touch. Within Reach.™ Whether it’s to study a new allergen in Akron, help set up your practice in Provo, create a custom extract mixture, or provide a large quantity of house dust mites for your study. Whatever it is and whenever you need it, GREER® is within reach. And always in touch.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com

Pharmaceutics International, Inc. (Pii) Concept-to-Clinic-to-Commercialization Pharmaceutics Know-How™. Pharmaceutics International, Inc. (Pii) is a science-driven contract development and manufacturing organization (CDMO) located in Hunt Valley, MD, USA, offering unparalleled scientific insight and depth of product knowledge to supply high-quality dosage forms that enhance the lives of patients worldwide. Founded in 1994, Pii has grown from 12 employees to more than 270 scientists and support staff. With more than 360,000 square feet of operating space, Pii's cGMP and DEA-registered facilities are state-of-the-art. More than 70 manufacturing suites include containment areas for handling high potency compounds and hormones, dedicated manufacturing suites for oral products (e.g., soft gels) and injectables (e.g., vials, syringes, cartridges), a formulation development center, and analytical and micro laboratories.

Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. The Company is dedicated to developing and bringing to market therapies that target each class of molecular pathways regulating apoptosis, or programmed cell death, in a wide range of indications. Headquartered in Suzhou, China, we are a rapidly growing company with offices in three countries. Ascentage Pharma has built a pipeline of seven clinical drug candidates, including novel, highly selective and potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, additional apoptotis inhibitors targeting IAP and MDM2-p53 proteins. The pipeline is balanced by next-generation tyrosine kinase inhibitors (TKIs) aimed at treatment induced resistance mutations. Ascentage Pharma is conducting more than 40 clinical trials in specific regions worldwide.

We provide a smart alternative to wood, steel and aluminum. Our fiberglass reinforced polymer (FRP) building material is strong, lightweight and non-conductive. It won't corrode, rot, rust or warp so it's ideal for harsh environments. Because of these properties, our products have been used in many noteworthy projects — from the Bellagio fountains in Las Vegas to a pedestrian bridge near Ground Zero in New York City. For more than 40 years, Bedford has earned customers'​ trust by providing quality products at a fair price, delivered on time, with the same high level of service we expect for ourselves. No matter what the customer's vision, we can custom-engineer and fabricate the best solution, then stand behind it with our industry leading warranty.

As a medium sized, family-owned company in its second generation we are known internationally as a "Specialist for Macromolecular Chemistry"​. Starting with the development of polymer dispersions for adhesives, our core business, today, is the development, production, and marketing of polymers in the form of emulsions, solutions, or as mass polymers.

Met zorg voor mens en milieu produceren en verhandelen we chemische bouwstenen vanuit onze 3 productie sites te Hemiksem, Oostende en Friendly (USA) en onze dochteronderneming China. Dankzij de inzet van een 220-tal medewerkers wordt een omzet van € 57M (2020) gerealiseerd. Proviron ontwikkelt functionele chemicaliën uit hernieuwbare grondstoffen met een duidelijk herkenbare meerwaarde toegepast als weekmakers voor polymeren, kunststoffen of plastics; prebiotische veevoeder-additieven, functionele monomeren en surfactanten voor watergedragen systemen. Daarnaast is Proviron baanbrekend in het onderzoek naar microalgen.